In the AI stack battleground, Alphabet is likely to win the race, but Microsoft is positioned to win the marathon.

The leading approach to the simplex method, a widely used technique for balancing complex logistical constraints, can’t get ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.27% on an annualized basis producing an average annual return of 18.42%. Currently, Vertex Pharmaceuticals ...

It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...

Vertex said Tuesday that David DeStefano is retiring as president and chief executive, effective Nov. 10. The company added that its board has named Christopher Young as its new president and CEO, ...

EXCLUSIVE: Even with Mortal Kombat II‘s release still a ways away, New Line is already gearing up to expand the film franchise with a third installment. After penning and executive producing the ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...